Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells
- PMID: 8428797
- DOI: 10.1002/ijc.2910530314
Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells
Abstract
In order to develop a more effective method of immunotherapy we have transfected mouse interleukin-2 (IL2) or mouse interleukin-4 (IL4) cDNA into a spontaneous non-immunogenic murine lung cancer. Lewis lung carcinoma (LLC). IL2 cDNA transfection more strongly decreases tumorigenicity of LLC than IL4 cDNA transfection. Recombinant-human-IL2 treatment of mice that were transplanted with untransfected LLC could not prolong their survival. In contrast, vaccination with IL2-cDNA-transfected LLC (LLC-IL2) and LLC-IL2 mixed with IL4-cDNA-transfected LLC (LLC-IL4) could significantly suppress tumor growth of LLC in a tumor-specific manner. The vaccination with LLC-IL2 mixed with the same number of LLC-IL4 cells was more suppressive to the growth of LLC than that with LLC-IL2 cells alone, while LLC-IL4 vaccination alone was ineffective. Nude, severe-combined-immune-deficient (SCID) and beige mice were unable to reject LLC-IL2 cells. However, immunodeficient mice responded to LLC-IL2, but not to LLC, since their survival times after transplantation with LLC-IL2 cells were significantly longer than the survival time of normal or immunodeficient mice transplanted with untransfected LLC cells. We conclude that vaccination with IL2-producing tumors and, with more pronounced effect, in combination with IL4-producing tumors, is able to induce an immune response to this normally non-immunogenic tumor. Tumor rejection appears to be achieved by the combined activity of CTL and NK cells. This strategy has potential for new immunotherapeutic interventions in cancer patients.
Similar articles
-
[Induction of tumor immunity by cytokine cDNA transfected Lewis lung carcinoma].Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Dec;30 Suppl:48-51. Nihon Kyobu Shikkan Gakkai Zasshi. 1992. PMID: 1306238 Japanese.
-
Gene therapy for Lewis lung carcinoma with tumor necrosis factor and interleukin 2 cDNAs co-transfected subline.Gene Ther. 1994 Jul;1(4):269-75. Gene Ther. 1994. PMID: 7584091
-
Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells.Int J Cancer. 1997 Dec 10;73(6):844-9. doi: 10.1002/(sici)1097-0215(19971210)73:6<844::aid-ijc14>3.0.co;2-4. Int J Cancer. 1997. PMID: 9399664
-
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.Dan Med J. 2013 Dec;60(12):B4774. Dan Med J. 2013. PMID: 24355457 Review.
-
IL2 treatment for cancer: from biology to gene therapy.Br J Cancer. 1992 Dec;66(6):992-8. doi: 10.1038/bjc.1992.400. Br J Cancer. 1992. PMID: 1457368 Free PMC article. Review.
Cited by
-
Antibody-cytokine fusion proteins: applications in cancer therapy.Expert Opin Biol Ther. 2008 May;8(5):609-32. doi: 10.1517/14712598.8.5.609. Expert Opin Biol Ther. 2008. PMID: 18407765 Free PMC article. Review.
-
Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6.Jpn J Cancer Res. 2001 Jul;92(7):768-77. doi: 10.1111/j.1349-7006.2001.tb01160.x. Jpn J Cancer Res. 2001. PMID: 11473728 Free PMC article.
-
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.Cancer Immunol Immunother. 2018 Sep;67(9):1381-1391. doi: 10.1007/s00262-018-2194-0. Epub 2018 Jul 4. Cancer Immunol Immunother. 2018. PMID: 29971465 Free PMC article.
-
Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses.Ann Surg Oncol. 1996 Jan;3(1):15-23. doi: 10.1007/BF02409046. Ann Surg Oncol. 1996. PMID: 8770297
-
Immunomodulation of cancer: potential use of selectively replicating agents.J Clin Invest. 2000 May;105(9):1173-6. doi: 10.1172/JCI10026. J Clin Invest. 2000. PMID: 10791989 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical